<DOC>
	<DOCNO>NCT01222884</DOCNO>
	<brief_summary>The purpose study compare efficacy safety intravenous iron isomaltoside 1000 intravenous iron sucrose patient suffer Stage 5 Chronic Kidney Disease Dialysis Therapy ( CKD-5D ) .</brief_summary>
	<brief_title>A Randomized , Comparative , Open-label Study IV Monofer® Administered Maintenance Therapy Single Repeated Bolus Injections Comparison With IV Iron Sucrose Subjects With CKD-5D</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Subjects diagnosis CKD5D , dialysis therapy least 90 day prior inclusion , include meet follow criterion : 1 . Men woman , age 18 year great . 2 . Subjects diagnose CKD5D haemodialysis therapy least 90 day . 3 . Life expectancy beyond 12 month Principal Investigator 's judgement . 4 . Willingness ability participate Informed Consent . 5 . Hb concentration 9.5 g/dL 12.5 g/dL ( value include ) Screening Visit 1a Screening Visit 1b ( screen Visit 1a Visit 1b must separate least 1 week ) . 6 . Serum ferritin &lt; 800 ng/mL . 7 . Transferrin Saturation &lt; 35 % . 8 . Subjects receive ESA treatment dose stable previous 4 week prior screen ( 1 miss dose allow . Dose keep stable study period ) . 9 . Subjects receive IV iron average 100 mg/week previous 4 week ( 1 miss dose allow ) . 1 . Anaemia cause primarily factor renal related anaemia . 2 . Iron overload disturbance utilization iron ( e.g . haemochromatosis haemosiderosis ) . 3 . Patients currently undergo treatment immunosuppresives ( low dose steroid allow study conduct dosages 10 mg prednisolone/day equivalent . If possible dosage keep constant study ) . 4 . Difference Hb ≥ 1.0 g/dL screening ( Visits 1a 1b ) . 5 . Patients history multiple allergy . 6 . Decompensated liver cirrhosis active hepatitis [ Alanine Aminotransferase ( ALT ) &gt; 3 time normal ] history Hepatitis B C. 7 . Active acute chronic infection ( assessed clinical judgement ) , supply White Blood Cells ( WBC ) C reactive protein ( CRP ) . 8 . Rheumatoid arthritis symptom sign active joint inflammation . 9 . Pregnancy nursing . [ To avoid pregnancy , woman postmenopausal ( least 12 month must elapse since last menstruation ) , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product : Contraceptive pill , Intrauterine Devices ( IUD ) , contraceptive depot injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ] 10 . Blood transfusion within previous 12 week . 11 . Planned elective surgery next 8 week . 12 . Participation clinical trial within past 30 day , long , study drug pass five halflives prior screen . 13 . Untreated Vitamin B12 folate deficiency . 14 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study . Examples include Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>